Identifying novel targets for cardioprotection with non-traditional animal models
Ended Project Grant Awarded Last action
- Award ID
- R41HG011577
- Recipient
-
Fauna Bio Incorporated UEI U55RWLCE4VZ3
- Awarding agency
-
National Human Genome Research Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,652,136
Award facts
- Assistance listing
- 93.172 Human Genome Research
- Completion date
- Funding
-
- $1,101,424.00 Federal
- $550,712.00 Non-federal
- Place of performance
- Newark, CA 94560, USA
Award details come from USAspending.gov.
Description
- Abstract
- Low-cost sequencing has ushered in a new ERA of drug discovery that can that utilize genomic information from hundreds of thousands of people. However, humans are a limited resource for identifying novel drug targets, and attempts at therapeutic development often rely on an already well-known set of genes and pathways. Greater potential for discovery exists if we broaden our search throughout the animal kingdom. In particular, animal adaptations for disease resistance have great potential to unearth novel biological pathways to counteract human diseases. Hibernating mammals are an especially rich resource to inspire novel therapeutics as they exhibit numerous transient phenotypes that mirror critical human health problems such as ischemia-reperfusion injury, alzheimer's disease, osteoporosis, muscle atrophy, and obesity/diabetes, yet they are able to avoid or reverse pathologies. A systematic understanding of the gene networks utilized to generate the protective and healing phenotypes of hibernators has great potential to reveal novel therapeutic avenues; however, targets that reproduce across independent datasets, including associating with the same phenotype across multiple species have higher likelihood of translating to humans. In this proposal, specifically, we propose to (1) obtain high-throughput phenotypic data to test our platform (2) create a better model for identifying targets based on machine learning and (3) grow our approach into new disease areas. Our long-term vision is to develop a genomics discovery platform centered on hibernating animals for all of the diseases discussed above. We believe that our approach will identify novel therapeutic targets that will translate to humans, and we will advance our discoveries through strategic pharmaceutical partnerships.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $177,278 | $0 | |
| Amendment | $177,278 | $177,278 | |
| Amendment | $373,434 | $0 | |
| Original award | $373,434 | $373,434 |
Quick answers
Who received award R41HG011577?
R41HG011577 was awarded to Fauna Bio Incorporated by National Human Genome Research Institute (National Institutes of Health) on June 1, 2021.
How much is award R41HG011577 worth?
$1,652,136 has been obligated on R41HG011577: $1,101,424 in federal funding and $550,712 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award